Cargando…

Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states

BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventat...

Descripción completa

Detalles Bibliográficos
Autores principales: Privatt, Sara R., Braga, Camila Pereira, Johnson, Alicia, Lidenge, Salum J., Berry, Luke, Ngowi, John R., Ngalamika, Owen, Chapple, Andrew G., Mwaiselage, Julius, Wood, Charles, West, John T., Adamec, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470137/
https://www.ncbi.nlm.nih.gov/pubmed/37653396
http://dx.doi.org/10.1186/s40170-023-00316-0
_version_ 1785099619918675968
author Privatt, Sara R.
Braga, Camila Pereira
Johnson, Alicia
Lidenge, Salum J.
Berry, Luke
Ngowi, John R.
Ngalamika, Owen
Chapple, Andrew G.
Mwaiselage, Julius
Wood, Charles
West, John T.
Adamec, Jiri
author_facet Privatt, Sara R.
Braga, Camila Pereira
Johnson, Alicia
Lidenge, Salum J.
Berry, Luke
Ngowi, John R.
Ngalamika, Owen
Chapple, Andrew G.
Mwaiselage, Julius
Wood, Charles
West, John T.
Adamec, Jiri
author_sort Privatt, Sara R.
collection PubMed
description BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other. METHODS: To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression. CONCLUSIONS: This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-023-00316-0.
format Online
Article
Text
id pubmed-10470137
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104701372023-09-01 Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states Privatt, Sara R. Braga, Camila Pereira Johnson, Alicia Lidenge, Salum J. Berry, Luke Ngowi, John R. Ngalamika, Owen Chapple, Andrew G. Mwaiselage, Julius Wood, Charles West, John T. Adamec, Jiri Cancer Metab Research BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other. METHODS: To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression. CONCLUSIONS: This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-023-00316-0. BioMed Central 2023-08-31 /pmc/articles/PMC10470137/ /pubmed/37653396 http://dx.doi.org/10.1186/s40170-023-00316-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Privatt, Sara R.
Braga, Camila Pereira
Johnson, Alicia
Lidenge, Salum J.
Berry, Luke
Ngowi, John R.
Ngalamika, Owen
Chapple, Andrew G.
Mwaiselage, Julius
Wood, Charles
West, John T.
Adamec, Jiri
Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title_full Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title_fullStr Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title_full_unstemmed Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title_short Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
title_sort comparative polar and lipid plasma metabolomics differentiate kshv infection and disease states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470137/
https://www.ncbi.nlm.nih.gov/pubmed/37653396
http://dx.doi.org/10.1186/s40170-023-00316-0
work_keys_str_mv AT privattsarar comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT bragacamilapereira comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT johnsonalicia comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT lidengesalumj comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT berryluke comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT ngowijohnr comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT ngalamikaowen comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT chappleandrewg comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT mwaiselagejulius comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT woodcharles comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT westjohnt comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates
AT adamecjiri comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates